![]() ![]() ![]() Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One, through its wholly owned subsidiary Vocan, has developed, and filed for patent protection, a proprietary process for producing psilocybin using engineered bacteria. As we take the necessary steps to advance the product, we will look to build out a pipeline of potential partners who desire to use high quality, high purity psilocybin in their treatments and studies,” stated Joel Shacker, Core One CEO.Ībout Core One Labs Inc. We are positioning ourselves as a leader in the psychedelic space through our innovative and game changing advancements in the psilocybin space. “ Core One Labs has taken another step towards being first to market with this cost-efficient biosynthetic psilocybin. Vocan is looking to expand production capabilities to supply its API grade psilocybin to licensed contract development and manufacturing organization (CDMO) that can capsulize the Company’s raw biosynthesized psilocybin enabling the dispensing of customized concentrations of psilocybin for deployment to physicians that have applied for and obtained approval on behalf of their patients for access to psilocybin under Health Canada’s Special Access Program 1. This advertisement has not loaded yet, but your article continues below. The proprietary production system for biosynthesized psilocybin that has been developed by Vocan scientists (Company press release dated January 21, 2022) is a system that results in a stereochemically correct psilocybin API that can be precisely calibrated to provide the exact and appropriate dosage while ensuring a high level of purity.Ĭurrently the Company, through its scientific research and development arm at Vocan, is in the process of expanding its production capabilities to allow for the deployment of its proprietary psilocybin API to GMP compliant production facilities that could further distribute product to pharmaceutical companies, and clinical research organizations and facilities, providing a cost effective, reliable, and chemically stable psilocybin source for research efforts. The next issue of Financial Post Top Stories will soon be in your inbox. If you don't see it, please check your junk folder. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |